DexCom, Inc. (NASDAQ:DXCM) Holdings Trimmed by Centaurus Financial Inc.

Centaurus Financial Inc. lowered its holdings in DexCom, Inc. (NASDAQ:DXCM) by 8.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,400 shares of the medical device company’s stock after selling 212 shares during the period. Centaurus Financial Inc.’s holdings in DexCom were worth $161,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of DXCM. Taylor Frigon Capital Management LLC lifted its stake in DexCom by 51.6% in the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after acquiring an additional 11,075 shares in the last quarter. Brooktree Capital Management acquired a new position in shares of DexCom in the 3rd quarter valued at about $683,000. National Pension Service lifted its position in shares of DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after purchasing an additional 37,363 shares in the last quarter. Intact Investment Management Inc. acquired a new stake in shares of DexCom during the third quarter worth approximately $650,000. Finally, Waters Parkerson & CO. LLC grew its position in DexCom by 4.2% during the second quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock valued at $30,912,000 after purchasing an additional 10,892 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $78.10 on Thursday. The company has a market capitalization of $30.51 billion, a PE ratio of 46.77, a price-to-earnings-growth ratio of 2.38 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company’s fifty day moving average price is $71.11 and its 200 day moving average price is $88.51.

Wall Street Analyst Weigh In

A number of research firms have issued reports on DXCM. Sanford C. Bernstein increased their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Oppenheimer reduced their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Raymond James cut their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Finally, JPMorgan Chase & Co. boosted their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $104.59.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,431 shares of company stock worth $399,319. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.